Tonix Pharmaceuticals Holding (TNXP) EV/EBIT: History & Chart

Tonix Pharmaceuticals Holding Corp.(TNXP)

Biotechnology · Berkeley Heights, NJ

$7.70-0.38 (-4.65%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and diagnostic tools, all aimed at combating human illnesses and easing patient discomfort. The company boasts a comprehensive pipeline of potential treatments spanning several key medical fields: immunology, rare conditions, infectious diseases, and central nervous system (CNS) disorders. In the realm of immunology, Tonix is progressing with biologics designed to address organ transplant rejection, various autoimmune diseases, and certain forms of cancer. A prominent candidate here is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, which is being investigated for its utility in preventing both allograft and xenograft rejection, as well as in treating autoimmune disorders. Its rare disease initiatives include TNX-2900, a specific treatment candidate for Prader-Willi syndrome. The infectious disease segment features a diverse array of programs: TNX-801, a vaccine designed to offer protection against smallpox and monkeypox. TNX-1840 and TNX-1850, which are live virus vaccines based on the company's recombinant pox vaccine (RPV) platform, targeting COVID-19. TNX-3500, a small molecule antiviral drug for the treatment of acute COVID-19. TNX-102 SL, a small molecule medication under investigation for Long COVID, a persistent post-acute COVID-19 condition. Finally, the CNS portfolio encompasses both small molecules and biologics intended to manage pain, neurological conditions, psychiatric ailments, and addiction. Notably, TNX-102 SL is also in mid-Phase 3 development for alleviating fibromyalgia symptoms. Other CNS candidates include TNX-1900, which is being developed to prevent migraine headaches, and TNX-1300, a biologic aimed at treating cocaine intoxication. The company was established in 2007 and maintains its headquarters in Chatham, New Jersey.

Berkeley Heights, NJ

142 employees

www.tonixpharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Seth Lederman

View full financials

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Tonix Pharmaceuticals Holding Corp. (TNXP)	$122.66M	N/A	N/A	N/A	N/A
BGM Group Ltd. (BGM)vs ›	$122.43M	N/A	N/A	N/A	N/A
TuHURA Biosciences, Inc. (HURA)vs ›	$124.18M	N/A	N/A	N/A	N/A
Entera Bio Ltd. (ENTX)vs ›	$124.70M	N/A	3.95x	3.95x	3.95x
enGene Holdings Inc. (ENGN)vs ›	$120.58M	N/A	N/A	N/A	N/A
Seer, Inc. (SEER)vs ›	$120.41M	N/A	N/A	N/A	N/A
Cibus, Inc. (CBUS)vs ›	$119.84M	N/A	N/A	N/A	N/A
LENZ Therapeutics, Inc. (LENZ)vs ›	$118.83M	N/A	N/A	N/A	N/A
Tenaya Therapeutics, Inc. (TNYA)vs ›	$118.59M	N/A	N/A	N/A	N/A
NRx Pharmaceuticals, Inc. (NRXP)vs ›	$127.29M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EV/EBIT RATIO

TTM

Tonix Pharmaceuticals Holding Corp. (TNXP)

$122.66M

N/A

BGM Group Ltd. (BGM)vs ›

$122.43M

N/A

TuHURA Biosciences, Inc. (HURA)vs ›

$124.18M